Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives $9.00 Consensus Price Target from Analysts
Outlook Therapeutics, Inc. (NASDAQ:OTLK) has received a consensus recommendation of “Buy” from the seven ratings firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $9.00.
Separately, Zacks Investment Research downgraded shares of Outlook Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 6th.
NASDAQ OTLK opened at $0.86 on Monday. Outlook Therapeutics has a 1 year low of $0.52 and a 1 year high of $10.96. The firm has a market cap of $24.77 million, a price-to-earnings ratio of -0.43 and a beta of -0.90. The company has a fifty day moving average price of $0.97 and a 200-day moving average price of $1.50.
Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in Outlook Therapeutics by 712.1% during the second quarter. Vanguard Group Inc. now owns 396,001 shares of the company’s stock worth $824,000 after acquiring an additional 347,238 shares during the period. LVW Advisors LLC increased its position in shares of Outlook Therapeutics by 37.6% during the 3rd quarter. LVW Advisors LLC now owns 389,088 shares of the company’s stock valued at $580,000 after purchasing an additional 106,293 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Outlook Therapeutics during the 3rd quarter valued at $83,000. Finally, Cormorant Asset Management LP bought a new stake in shares of Outlook Therapeutics during the 2nd quarter worth $32,000. 3.35% of the stock is owned by institutional investors.
About Outlook Therapeutics
Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.
Featured Story: What do I need to know about analyst ratings?
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.